Through alterations in the mechanisms of TGF-β signaling, for instance, disabling mutations in TβRII and Smad4, cancer cells develop tolerance to the tumor-suppressive effects of TGF-β in advanced stages of cancer [13,14,42]. Here, TGFBR2 is linked to cancer.